An oncologists looks at “needy” patients from the perspective of patients “in need.” (ASCO Connection)
Worth more than a thousand words: A nurse’s pictorial journey from tanning beds to skin cancer. (Yahoo News)
Positive results from a preliminary clinical study of a first-ever ERK1/2 inhibitor for cancer. (American Association for Cancer Research)
About 1 in 10 women who might benefit from radiation therapy after breast-conserving surgery don’t get it. (Fox Chase Cancer Center)
An old drug could find new life as a potential option for patients with triple-negative breast cancer. (Case Western Reserve University Medicine)
Combining a PARP inhibitor with another novel drug class known as a BET inhibitor produced encouraging activity in laboratory models of ovarian cancer.
Frequent monitoring of genetic changes in response to treatment — as often as every month or two — could improve outcomes in chronic lymphocytic leukemia. (Nature Communications, Weill Cornell Medicine)
Using radiation therapy to boost the activity of natural killer cells reduced metastasis in a preclinical model of bone cancer. (UC Davis Health)
Exelixis said the FDA allowed an expanded indication for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma.
Somewhat counterintuitively, tumors that have more mutations might be most responsive to treatment with immunotherapy. (Johns Hopkins Medicine)